Endo International (ENDP) Given a $7.00 Price Target by Cantor Fitzgerald Analysts

Cantor Fitzgerald set a $7.00 target price on Endo International (NASDAQ:ENDP) (TSE:ENL) in a research note published on Thursday morning. The firm currently has a hold rating on the stock.

A number of other equities research analysts also recently issued reports on ENDP. Piper Jaffray Companies reiterated a hold rating and set a $9.00 price objective on shares of Endo International in a research note on Sunday, September 17th. Zacks Investment Research upgraded shares of Endo International from a strong sell rating to a hold rating in a research note on Monday, September 25th. Goldman Sachs Group started coverage on shares of Endo International in a research note on Thursday, September 28th. They set a sell rating and a $7.00 price objective on the stock. ValuEngine upgraded shares of Endo International from a hold rating to a buy rating in a research note on Monday, October 2nd. Finally, Royal Bank of Canada set a $9.00 price objective on shares of Endo International and gave the stock a hold rating in a research note on Tuesday, October 17th. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Hold and an average price target of $11.27.

Shares of Endo International (NASDAQ ENDP) traded up $0.03 during trading on Thursday, reaching $7.95. 4,319,100 shares of the company’s stock were exchanged, compared to its average volume of 7,334,944. The firm has a market capitalization of $1,780.00, a P/E ratio of -0.41, a price-to-earnings-growth ratio of 2.73 and a beta of 0.59. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. Endo International has a 12-month low of $5.77 and a 12-month high of $14.45.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. The firm had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The business’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.01 earnings per share. research analysts forecast that Endo International will post 3.67 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Riverhead Capital Management LLC boosted its stake in shares of Endo International by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after purchasing an additional 5,887 shares in the last quarter. Bank of Hawaii bought a new position in Endo International in the 2nd quarter valued at approximately $180,000. LMR Partners LLP bought a new position in Endo International in the 3rd quarter valued at approximately $148,000. Flinton Capital Management LLC raised its holdings in Endo International by 64.4% in the 2nd quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock valued at $228,000 after buying an additional 7,990 shares during the last quarter. Finally, Schroder Investment Management Group bought a new position in Endo International in the 2nd quarter valued at approximately $330,000. Institutional investors own 93.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Endo International (ENDP) Given a $7.00 Price Target by Cantor Fitzgerald Analysts” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/01/15/endo-international-endp-given-a-7-00-price-target-by-cantor-fitzgerald-analysts.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply